Skip to main content

McEnany Patrick J's Form 4 filing

Catalyst Pharmaceuticals, Inc. (CPRX) · filed May 17, 2023

Accession no.
0001161697-23-000300
Filed
May 17, 2023
Trade date
May 15-16, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $346.0K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
McEnany Patrick JCIK 0000929985Director, Officer (President and CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 15, 2023Common stock, par value $0.001 per shareMOption exerciseAcquired+26,151$0.79+$20,659.293,971,587Direct
May 15, 2023Common stock, par value $0.001 per shareSSaleDisposed−26,151$13.23F2−$345,977.733,945,436Direct
May 16, 2023Common stock, par value $0.001 per shareMOption exerciseAcquired+173,849$0.79+$137,340.714,119,285Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 15, 2023Common StockMOption exerciseDisposed−26,151$0.00$03,101,516Direct
May 16, 2023Common StockMOption exerciseDisposed−173,849$0.00$02,927,667Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $13.20 to $13.285 per share.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)